Taunis, as I said in an earlier post and as you and Xena have also stated, it is way too early to even think about a buy-out. First of all, a BP is not going to buy us out at this time. It is way too early for them to risk shareholder equity in a buy-out. They need to see more data. And by the time most of them would be comfortable offering a price, we shareholders will have seen enough data to realize that the risk in this small biotech has been at least somewhat mitigated due to the same data. As you said, the price for this company, if we have what some of us THINK we have, is at this time "inestimable". I am getting the impression that some on this board have not fully appreciated the potential here, and I for one would like to see the story continue to unfold before a buy-out is even considered.
If a buy-out at this point would make some of us "wealthy", then IMHO, some of us have too much riding on an early stage biotech at this point in the process. It may very well work out, and I certainly hope it does, but it is akin to playing the roulette wheel in Vegas. Patience is the most important characteristic of successful investors.
Market Data 
Markets 
AI
